JP2022515152A5 - - Google Patents
Info
- Publication number
- JP2022515152A5 JP2022515152A5 JP2021535665A JP2021535665A JP2022515152A5 JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5 JP 2021535665 A JP2021535665 A JP 2021535665A JP 2021535665 A JP2021535665 A JP 2021535665A JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192700A JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782317P | 2018-12-19 | 2018-12-19 | |
| US62/782,317 | 2018-12-19 | ||
| PCT/US2019/067563 WO2020132291A1 (en) | 2018-12-19 | 2019-12-19 | Baff-r bispecific t-cell engager antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192700A Division JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515152A JP2022515152A (ja) | 2022-02-17 |
| JP2022515152A5 true JP2022515152A5 (https=) | 2022-12-21 |
| JPWO2020132291A5 JPWO2020132291A5 (https=) | 2022-12-21 |
Family
ID=71098268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535665A Pending JP2022515152A (ja) | 2018-12-19 | 2019-12-19 | Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 |
| JP2024192700A Pending JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192700A Pending JP2025032075A (ja) | 2018-12-19 | 2024-11-01 | Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200199232A1 (https=) |
| EP (1) | EP3897720A4 (https=) |
| JP (2) | JP2022515152A (https=) |
| KR (1) | KR20210104816A (https=) |
| CN (2) | CN113412124A (https=) |
| AU (1) | AU2019404282A1 (https=) |
| CA (1) | CA3123599A1 (https=) |
| WO (1) | WO2020132291A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CA3261672A1 (en) * | 2022-07-19 | 2024-01-25 | Novartis Ag | TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITOR ANTIBODIES |
| WO2024074145A1 (zh) * | 2022-10-08 | 2024-04-11 | 盛禾(中国)生物制药有限公司 | 一种结合baffr和cd3的双特异性抗体及其应用 |
| AU2024227909A1 (en) * | 2023-02-28 | 2025-08-14 | Mayo Foundation For Medical Education And Research | Molecules that bind to b-cell activating factor receptor polypeptides |
| WO2025221674A1 (en) * | 2024-04-15 | 2025-10-23 | Eli Lilly And Company | Baffr x cd3 bispecific antibodies and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2216342B1 (en) * | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| RU2679124C2 (ru) * | 2012-11-06 | 2019-02-06 | Байер Фарма Акциенгезельшафт | Препарат для биспецифических активаторов т-клеток (bite) |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| AU2015295242B2 (en) * | 2014-07-31 | 2020-10-22 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| EP3778640A1 (en) * | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| EP3916018A1 (en) * | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US10072088B2 (en) * | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| CN116063544A (zh) * | 2016-02-03 | 2023-05-05 | 安进研发（慕尼黑）股份有限公司 | Bcma和cd3双特异性t细胞接合抗体构建体 |
| KR20250084978A (ko) * | 2016-06-06 | 2025-06-11 | 시티 오브 호프 | Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도 |
| CN116041514A (zh) * | 2016-06-06 | 2023-05-02 | 希望之城 | Baff-r抗体及其用途 |
| JP2019529499A (ja) * | 2016-09-30 | 2019-10-17 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 組織指向性発現を用いた抗体ベースの遺伝子治療 |
| KR20210129125A (ko) * | 2019-02-20 | 2021-10-27 | 시티 오브 호프 | Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도 |
-
2019
- 2019-12-19 WO PCT/US2019/067563 patent/WO2020132291A1/en not_active Ceased
- 2019-12-19 US US16/721,485 patent/US20200199232A1/en not_active Abandoned
- 2019-12-19 KR KR1020217022324A patent/KR20210104816A/ko not_active Ceased
- 2019-12-19 CA CA3123599A patent/CA3123599A1/en active Pending
- 2019-12-19 CN CN201980089634.XA patent/CN113412124A/zh active Pending
- 2019-12-19 JP JP2021535665A patent/JP2022515152A/ja active Pending
- 2019-12-19 CN CN202511607565.0A patent/CN121405815A/zh active Pending
- 2019-12-19 US US17/414,867 patent/US20220056132A1/en not_active Abandoned
- 2019-12-19 EP EP19900284.1A patent/EP3897720A4/en active Pending
- 2019-12-19 AU AU2019404282A patent/AU2019404282A1/en active Pending
-
2024
- 2024-11-01 JP JP2024192700A patent/JP2025032075A/ja active Pending